희귀질환 치료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the rare disease treatment market size is expected to grow from USD 242.5 billion in 2025 to USD 271.07 billion in 2026 and is forecast to reach USD 472.89 billion by 2031 at 11.8% CAGR over 2026-2031.

This report is Segmented by Disease Type (Oncological Rare Diseases, Neurological Disorders, and More), Therapy Type (Small-Molecule Drugs, Biologics & Monoclonal Antibodies, and More), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Rare Disease Treatment Market Trends and Insights

Government Incentives & Global Orphan-Drug Exclusivity

Extended exclusivity and tax credits continue to underwrite innovation within the rare disease treatment market. In the United States, seven-year exclusivity and 25% clinical trial tax credits lower net risk, while the European Union grants 10-year protection that can extend to 12 years for pediatric compliance. Priority Review Vouchers worth roughly USD 150 million add further return potential, as shown by the sale following DAYBUE approval for Rett syndrome. Such incentives help translate basic-science breakthroughs into commercially viable therapies.

Growing FDA/EMA Rare-Disease Approvals Pipeline

Regulators have embraced expedited mechanisms. The FDA cleared multiple gene therapies in 2024, including Kebilidi for aromatic L-amino acid decarboxylase deficiency. The EMA granted 17 orphan designations in 2023, demonstrating a steady flow of candidates. Together with the FDA START pilot and EMA PRIME schemes, these frameworks reduce review uncertainty and accelerate launches, fuelling market expansion.

Limited Patient Pools for Conventional RCTs

Ultra-rare conditions can involve only hundreds of patients worldwide, making standard randomised trials extremely difficult. Adaptive and basket designs help, but more than 50% of rare-disease studies still fail to publish results due to recruitment gaps.

Other drivers and restraints analyzed in the detailed report include:

1. Premium Pricing & Favourable Reimbursement Frameworks
2. Rapid Advances in Gene & Cell Therapies
3. Escalating Payor Push-Back on Six-Figure Price Tags

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Oncological rare diseases captured 41.89% of the rare disease treatment market share in 2025, underscoring their revenue dominance within the overall rare disease treatment market. This leadership reflects the high clinical unmet need and premium pricing associated with niche cancer therapeutics, particularly hematologic malignancies that benefit from targeted biologics and immunotherapies. The rare disease treatment market size for oncological indications is projected to maintain mid-single-digit growth as additional precision drugs secure approvals and expand addressable sub-cohorts. Neurological disorders, by contrast, are forecast to grow at a 12.62% CAGR through 2031, propelled by gene therapies such as Lenmeldy and Kebilidi that penetrate the blood-brain barrier and deliver potentially curative benefits . Regulatory pilots that shorten review timelines for neurodegenerative indications add further momentum.

Growth outside these two pillars remains steady yet meaningful. Metabolic disorders continue to rely on enzyme replacement and emerging gene-editing modalities that broaden lifetime treatment options. In contrast, immunological disorders absorb advances in monoclonal antibodies and engineered T-cell platforms. Infectious-disease applications, although smaller in value, attract interest for antimicrobial-resistance niches where orphan incentives offset limited volumes. Pipeline analysis shows roughly 18% of phase III assets now target neurological diseases, signaling sustained capital reallocation toward high-growth categories. Overall, disease-type diversification reduces portfolio risk for manufacturers and helps the rare disease treatment market achieve balanced long-term expansion.

Biologics and monoclonal antibodies accounted for 50.74% of 2025 revenue, maintaining their position at the center of the rare disease treatment market size, thanks to their proven efficacy and payer familiarity with chronic infusion models. Even so, gene and cell therapies are outpacing every other modality at a 12.88% CAGR, driven by a pipeline exceeding 700 active clinical programmes that target both well-characterised and ultra-rare mutations. Recent approvals across neurologic and hematologic categories validate adeno-associated virus vectors and encourage investment in next-generation capsids with enhanced tissue tropism.

The competitive interplay among modalities is widening. Small-molecule drugs preserve niche relevance for metabolic pathways and allosteric enzyme modulation, offering convenience and lower manufacturing complexity. RNA-based interventions, particularly siRNA agents, continue to face adoption challenges despite broader coverage, because annual treatment costs range from USD 375,000 for first-generation options, such as patisiran (ONPATTRO), to more than USD 1.6 million for newer, highly specialized siRNA therapies. Vutrisiran (Amvuttra), administered quarterly, reduces the administration burden and related healthcare utilization, giving it a potential cost-effectiveness edge over patisiran without compromising clinical benefit. Enzyme-replacement therapies remain central for lysosomal storage diseases; however, long-term switching studies suggest a gradual shift toward single-administration gene transfers. Collectively, these dynamics transform the therapeutic mix and heighten innovation pressure on incumbent biologics franchises within the rare disease treatment market.

Complete Report Scope:

• By Disease Type
  • Oncological Rare Diseases
  • Neurological Disorders
  • Metabolic Disorders
  • Hematologic Disorders
  • Immunological Disorders
  • Infectious Diseases
  • Others
• By Therapy Type
  • Small-Molecule Drugs
  • Biologics & Monoclonal Antibodies
  • Gene & Cell Therapy
  • RNA-based Therapy
  • Enzyme Replacement Therapy
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By End User
  • Hospitals
  • Specialty Clinics
  • Home-Care Settings
  • Research & Academic Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America accounted for 41.86% of rare disease treatment market share in 2025, reflecting the combination of FDA fast-track pathways, wide commercial insurance coverage, and strong academic research networks. Average launch timelines for orphan assets are two to three years shorter than in any other region, giving the United States an enduring first-mover advantage. Canada mirrors this momentum through its Priority Review program, although provincial budget caps delay uniform access by six to nine months. Europe follows closely; the EMA granted 17 new orphan designations in 2023, underscoring a robust centralised review process that cuts duplicative national filings. Nonetheless, disparate reimbursement rules mean Central and Eastern European countries cover fewer than half of approved therapies, creating a two-tier access environment.

Asia-Pacific is poised for the fastest 13.29% CAGR through 2031, driven chiefly by China's regulatory reforms that expanded the National Rare Diseases List from 121 to 207 conditions. The NMPA CARE scheme compresses review cycles to 130 working days for qualifying drugs, yet only 38% of FDA-cleared orphan therapies later gain Chinese approval, signalling ongoing localisation hurdles. Japan sustains leadership in ultra-rare neuromuscular indications; its 2024 approval of aceneuramic acid for GNE myopathy illustrates the value of targeted subsidy programs.South Korea and Singapore roll out tax credits and clinical-trial infrastructure grants that attract multinational studies, although small domestic populations still limit revenue upside. Collectively, growing diagnostic capacity, newborn screening expansion, and rising household income underpin the long-run contribution of Asia-Pacific to rare disease treatment market size. Latin America, the Middle East, and Africa represent nascent yet strategic frontiers with single-digit current penetration. Brazil's Health Surveillance Agency grants up to eight years of exclusivity for priority orphan drugs, but reimbursement remains case-by-case, creating unpredictable uptake. Saudi Arabia established a Rare Disease Registry in 2024, setting the stage for future market entry once local pharmacoeconomic guidelines mature.Multilateral organisations are piloting pooled procurement models to ease affordability barriers, though currency volatility and supply-chain gaps continue to restrain growth.

1. Novartis
2. Johnson & Johnson
3. Roche
4. AstraZeneca plc (Alexion)
5. Amgen
6. Pfizer
7. Takeda Pharmaceutical Co.
8. Sanofi
9. Bristol-Myers Squibb
10. Vertex Pharmaceuticals
11. BioMarin Pharmaceutical
12. CSL Behring
13. Ultragenyx Pharmaceutical
14. Regeneron Pharmaceuticals
15. Bluebird bio
16. Sarepta Therapeutics
17. Horizon Therapeutics
18. Genzyme (Sanofi)
19. PTC Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Government incentives & global orphan-drug exclusivity
  • 4.2.2 Growing FDA/EMA orphan-drug approvals pipeline
  • 4.2.3 Premium pricing & favourable reimbursement frameworks
  • 4.2.4 Rapid advances in gene & cell therapies
  • 4.2.5 Distributed manufacturing for personalised gene therapy (under-the-radar)
  • 4.2.6 AI-enabled virtual trials for ultra-rare cohorts (under-the-radar)
• 4.3 Market Restraints
  • 4.3.1 Limited patient pools for conventional RCTs
  • 4.3.2 Escalating payor push-back on six-figure price tags
  • 4.3.3 Viral-vector manufacturing bottlenecks (under-the-radar)
  • 4.3.4 Post-gene-therapy long-term safety liabilities (under-the-radar)
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Disease Type
  • 5.1.1 Oncological Rare Diseases
  • 5.1.2 Neurological Disorders
  • 5.1.3 Metabolic Disorders
  • 5.1.4 Hematologic Disorders
  • 5.1.5 Immunological Disorders
  • 5.1.6 Infectious Diseases
  • 5.1.7 Others
• 5.2 By Therapy Type
  • 5.2.1 Small-Molecule Drugs
  • 5.2.2 Biologics & Monoclonal Antibodies
  • 5.2.3 Gene & Cell Therapy
  • 5.2.4 RNA-based Therapy
  • 5.2.5 Enzyme Replacement Therapy
  • 5.2.6 Others
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Others
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Clinics
  • 5.4.3 Home-Care Settings
  • 5.4.4 Research & Academic Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Novartis AG
  • 6.3.2 Johnson & Johnson (Janssen)
  • 6.3.3 Roche Holding AG
  • 6.3.4 AstraZeneca plc (Alexion)
  • 6.3.5 Amgen Inc.
  • 6.3.6 Pfizer Inc.
  • 6.3.7 Takeda Pharmaceutical Co.
  • 6.3.8 Sanofi S.A.
  • 6.3.9 Bristol Myers Squibb
  • 6.3.10 Vertex Pharmaceuticals
  • 6.3.11 BioMarin Pharmaceutical
  • 6.3.12 CSL Behring
  • 6.3.13 Ultragenyx Pharmaceutical
  • 6.3.14 Regeneron Pharmaceuticals
  • 6.3.15 Bluebird bio
  • 6.3.16 Sarepta Therapeutics
  • 6.3.17 Horizon Therapeutics
  • 6.3.18 Genzyme (Sanofi)
  • 6.3.19 PTC Therapeutics

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment